About the Study
Erosive esophagitis is a severe gastrointestinal disease that if left untreated can damage the lining of the tissue and eventually erode the esophagus. Symptoms that people usually suffer from are heartburn, acid reflux, difficulty swallowing, and chest pain. These symptoms can become more serious leading to complications such as ulcers or precancerous cells in the GI tract. Treatments to relieve this usually consist of medications or sometimes surgery.
The study that we are conducting is in the 3rd phase and is testing the safety and efficacy of Tegoprazan used to help treat erosive esophagitis. There is a 0% chance of a placebo, so participants are either given 100 mg of Tegoprazan or 30 mg of lansoprazole (which is a heartburn medication). The purpose of this study is to see how well Tegoprazan works when healing the inflamed tissue in the esophagus and how well it reduces heartburn and other symptoms.
It will last anywhere between 30-36 weeks and includes 8 visits to our office and 1 phone call appointment. Study-related is available to participants in the trial at no cost and health insurance is not required nor needed. Compensation for this study is also available for participants.
- Confirmed erosive esophagitis by upper endoscopy
- No history of alcoholism
- No cancer in the past 5 years
- No Previous stomach surgery
- *Please note, that other conditions may apply